Sheldon Koenig
Chief Executive Officer presso ESPERION THERAPEUTICS, INC.
Patrimonio netto: 2 M $ in data 31/03/2024
Profilo
Sheldon L.
Koenig is the founder of Nuvig Therapeutics, Inc. He is currently the President, Chief Executive Officer & Director at Esperion Therapeutics, Inc. since 2021.
Previously, he worked as the Vice President at Merck & Co., Inc. from 2009 to 2015 and as the Chief Commercial Officer & Executive VP at Portola Pharmaceuticals LLC from 2019 to 2020.
He also held the position of Senior VP & Head-Cardiovascular Franchise at Sanofi Corp.
Mr. Koenig completed his undergraduate degree at Drexel University and obtained an MBA from Monmouth University.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
| 14/03/2024 | 766 816 ( 0.45% ) | 2 M $ | 31/03/2024 |
Posizioni attive di Sheldon Koenig
| Società | Posizione | Inizio |
|---|---|---|
| ESPERION THERAPEUTICS, INC. | Chief Executive Officer | 18/05/2021 |
Nuvig Therapeutics, Inc.
 Nuvig Therapeutics, Inc. BiotechnologyHealth Technology Nuvig Therapeutics, Inc. is a company that is focused on developing innovative therapies for patients with chronic autoimmune diseases. The company is based in Redwood City, CA. The company's goal is to induce natural mechanisms that restore immune homeostasis and rebalance immune function following inflammation. Nuvig Therapeutics was founded by Greg Coffey, Jeffrey V. Ravetch, Sheldon L. Koenig, Pamela B. Conley, Joanne M. Quan. Julie Anne Smith has been the CEO of the company since 2023. | Founder | - |
Precedenti posizioni note di Sheldon Koenig
| Società | Posizione | Fine |
|---|---|---|
| PORTOLA PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/08/2020 |
| MERCK & CO., INC. | Corporate Officer/Principal | 01/01/2015 |
| Sanofi Corp. | Corporate Officer/Principal | - |
Formazione di Sheldon Koenig
| Drexel University | Undergraduate Degree |
| Monmouth University | Masters Business Admin |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| MERCK & CO., INC. | Health Technology |
| ESPERION THERAPEUTICS, INC. | Health Technology |
| Aziende private | 3 |
|---|---|
Portola Pharmaceuticals LLC
 Portola Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Portola Pharmaceuticals, Inc. engaged in the development and commercialization of novel therapeutics in the areas of thrombosis, other hematologic disorders, and inflammation. It offers Andexxa and Bevyxxa medicines. The company was founded by Charles J. Homcy and David R. Philips on September 2, 2003 and is headquartered in South San Francisco, CA. | Health Technology |
| Sanofi Corp. | |
Nuvig Therapeutics, Inc.
Nuvig Therapeutics, Inc. BiotechnologyHealth Technology Nuvig Therapeutics, Inc. is a company that is focused on developing innovative therapies for patients with chronic autoimmune diseases. The company is based in Redwood City, CA. The company's goal is to induce natural mechanisms that restore immune homeostasis and rebalance immune function following inflammation. Nuvig Therapeutics was founded by Greg Coffey, Jeffrey V. Ravetch, Sheldon L. Koenig, Pamela B. Conley, Joanne M. Quan. Julie Anne Smith has been the CEO of the company since 2023. | Health Technology |
- Borsa valori
- Insiders
- Sheldon Koenig
